You might remember the Argus II implant from when it first gained market approval in the US back in 2013. The ambitious prosthesis is back, with researchers now looking to utilize the technology to treat patients with dry age-related macular degeneration (AMD). The effort forms part of a feasibility study, and early results are positive.
When its levels are slightly off-kilter, eye fluid can create pretty big problems for our vision. When blockages occur they can lead to a build up in pressure that destroys the optic nerve and causes blindness, a condition we know as glaucoma. In contrast, a lack of fluid can cause the eye to cave in and stop functioning, a disease known as phthisis bulbi. Currently, little can be done about these irreversible conditions once they take hold, but Fraunhofer researchers have a potential solution in the works by way of a microscopic pump that can be implanted in the eyeball to regulate ocular pressure.
Diabetic retinopathy is one of a number of nasty effects diabetes can have on the human body. The disease sees the development of leaky blood vessels in the eye that over time lead to permanent loss of vision. Though it is the leading cause of new cases of blindness in American adults, its progress can be slowed by certain drugs or laser treatment. But research has now uncovered a new protein found to drive the condition, raising the possibility of preventing it altogether.
We've already seen experimental "white canes" that allow blind users to get a sense of their surroundings via ultrasound and lasers.
Birmingham City University's XploR mobility cane, however, uses its
onboard electronics towards another end – to help users locate people
that they know.